In­flaRx plans to launch Covid an­ti­body with five-fig­ure price tag

A day af­ter win­ning emer­gency use au­tho­riza­tion for its Covid-19 an­ti­body, In­flaRx said it has enough sup­ply ready to treat sev­er­al thou­sand pa­tients. How­ev­er, the drug will like­ly have a five-fig­ure price tag.

In­flaRx is aim­ing to make vilo­be­limab avail­able as soon as pos­si­ble, CEO Niels Riede­mann said in a call with an­a­lysts on Wednes­day. The drug, to be launched un­der the name Go­hibic, was cleared for use in crit­i­cal­ly ill adults with­in 48 hours of re­ceiv­ing in­va­sive me­chan­i­cal ven­ti­la­tion or ex­tra­cor­po­re­al mem­brane oxy­gena­tion.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER